My interpretation is that K IV is not practical because patients can't stay hooked up to an IV long enough to make it effective due to the short half life of the drug staying in the body. That is why they stopped the trial as they had results from 2 patients that confirmed the p53 pathway activation and answered all the questions BP had for the trial. Also, Dr. B had earlier said that even one patient showing positive results regarding what they were looking for would be exceptional and we had 2 show early positive results so that was confirmation enough for all interested parties. No need to keep the dollars flowing in the trial as they would be better spent finalizing the Kevetrin oral delivery system. The K pill is going to be the game changer.

IMO Kevetrin at this point in time could be partnered up for major bucks. I wouldn't be surprised though if we wait until the pill is formulated as that should greatly increase the value of the K platform. Also, the K pill formulation should be pretty near completed if one is to believe their PR from last summer when they thought it would be ready for testing by healthy test patients by the end of 2017 so by now it should be really darn close to being done.